The impact of clinical pharmacist-led hypertension screening at the community pharmacy in Türkiye

Abstract

The aim of this study was to evaluate the impact of clinical pharmacist-led hypertension screening program (including referring high-risk individuals who are not aware of being hypertensive or prehypertensive to the physician) at a community pharmacy in Türkiye. This prospective observational pilot study was conducted in a community pharmacy located in Mersin-Türkiye between October 2017 and April 2018. Blood pressure measurements were performed by the clinical pharmacist at baseline and follow-up. The rate of participants who had high blood pressure measurements (≥140 mmHg for systolic and/or ≥90 mmHg for diastolic) was determined at the baseline by clinical pharmacist. According to the guidelines, participants with high blood pressure were referred directly to the physician by the clinical pharmacist. In the follow-up, the number of patients diagnosed with prehypertension or hypertension and the changes in their measurement of blood pressure were identified between baseline and follow-up. According to findings of clinical pharmacist-led blood pressure measurement, 23 (37.1%) out of 62 participants with high blood pressure were referred to the physician by the clinical pharmacist. In the follow-up, it was determined that 12 patients (52.2%) out of 23 participants were diagnosed with hypertension by a physician and eight patients (34.8%) out of 23 participants had prehypertensive. According to the findings of this pilot study, it was determined a positive impact of the clinical pharmacist-led hypertension screening program for high-risk individuals for hypertension.

Keywords

• Hypertension
• screening
• clinical pharmacist
• community pharmacy
• preventive health

References

1. [1] Aydogdu S, Guler K, Bayram F, Altun B, Derici U, Abaci A, Tukek T, Sabuncu T, Arici M, Erdem Y, Ozin B, Sahin I, Erturk S, Bitigen A, Tokgozoglu L. 2019 Turkish Hypertension Consensus Report. Turk Kardiyol Dern Ars. 2019 Sep;47(6):535-546. [CrossRef]
2. [2] Abaci A. The current status of cardiovascular risk factors in Turkey, Arch Turk Soc Cardiol 2011;39 Suppl 4:1-5. [CrossRef]
3. [3] TURKIYE KALP ve DAMAR HASTALIKLARI ONLEME ve KONTROL PROGRAMI. https://tkd.org.tr/TKDData/Uploads/files/Turkiye-kalp-ve-damar-hastaliklari-onleme-ve-kontrol-programi.pdf (accessed on 18 January, 2022).
4. [4] Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, Greg EW, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304): 957-980. [CrossRef]
5. [5] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Jama. 2003; 289(19): 2560-2571. [CrossRef]
6. [6] Elliot WJ, Black HR. Prehypertension. Nat. Clin. Pract. Cardiovasc. Med. 2007; 4(10): 538-548. [CrossRef]
7. [7] Turk Hipertansiyon Prevelans Calismasi. http://www.turkhipertansiyon.org/pdf/Turk_Hipertansiyon_Prevalans_Calismasi_Ozeti-1.pdf (accessed on 6 January, 2022).
8. [8] Onat A, Senocak M, Ornek E, Gozukara Y, Surdum-Avcı G, Karaaslan Y, et al. Türkiye’de Eriskinlerde Kalp Hastalıgı ve Risk Faktorleri Sikligi Taramasi: 5. Hipertansiyon ve Sigara İçimi. Turk Kardiyol Dern Ars. 1991; 19: 169-177.

9. [9] Tas F, Buyukbese MA. Hypertension Awareness and Role of the Nurse. TAF Prev. Med. Bull. 2013; 12(6): 729-734. [CrossRef]
10. [10] Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States. Jama. 2003; 290(2): 199-206. [CrossRef]
11. [11] Mangum SA, Kraenow KR, Narducci WA. Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J. Am. Pharm. Assoc. 1996; 43(1): 50-55. [CrossRef]
12. [12] Pongwecharak J, Treeranurat T. Screening for pre-hypertension and elevated cardiovascular risk factors in a Thai community pharmacy. Pharm World Sci. 2010; 32(3): 329-333. [CrossRef]
13. [13] Albasri A, Clark CE, Omboni S, McDonagh STJ, McManus RJ, Sheppard JP. Effective detection and management of hypertension through community pharmacy in England. The Pharmaceutical Journal. 2020; 304(7935). [CrossRef]
14. [14] Altun B, Arıcı M, Nergizoglu G, Derici U, Karatan O, Cetin T, et al. Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003. J Hypertens. 2005; 23(10): 1817-1823. [CrossRef]
15. [15] Altun B, Suleymanlar G, Utas C, Arinsoy T, Ates K, Ecder T, et al. Prevalence, awareness, treatment and control of hypertension in adults with chronic kidney disease in Turkey: results from the CREDIT study. Kidney Blood Press Res. 2012; 36(1): 36-46. [CrossRef]
16. [16] Waszyk-Nowaczyk M, Guzenda W, Plewka B, Mihalak M, Cerbin-Koczorowska M, Stryczynski L, et al. Screening services in a community pharmacy in Poznan (Poland) to increase early detection of hypertension. J Clin Med. 2020; 9(8): 2572. [CrossRef]
17. [17] Marfo AF, Owusu-Daaku FT. Evaluation of a pharmacist-led hypertension preventative and detection service in the Ghanaian community pharmacy: an exploratory study. Int J Pharm Pract. 2016; 24(5): 341-348. [CrossRef]
18. [18] Turk Kardiyoloji Derneği Ulusal Hipertansiyon Tedavi ve Takip Kılavuzu. https://tkd.org.tr/kilavuz/k03/3_2d304.htm?wbnum=1104 (accessed on 05 March, 2022).
19. [19] Sengul S, Akpolat T, Erdem Y, Derici U, Arici M, Sindel S, et al. Changes in hypertension prevalence, awareness, treatment, and control rates in Turkey from 2003 to 2012. J Hypertens. 2016; 34(6): 1208. [CrossRef]
20. [20] Machado M, Bajcar J, Guzzo GC, Einarson TR. Hypertension: sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007; 41(11): 1770-1781. [CrossRef]
21. [21] Pharmacy-Based Hypertension Management Model: Protocol and Guidelines. https://apps.who.int/iris/bitstream/handle/10665/107638/E85730.pdf?sequence=1&isAllowed=y (accessed on 13 January, 2022).
22. [22] George PP, Molina JAD, Cheah J, Chan SC, Lim BP. The evolving role of the community pharmacist in chronic disease management-a literature review. Ann Acad Med Singapore. 2010; 39(11): 861-867.
23. [23] Turk Hipertansiyon ve Bobrek Hastalikları Dernegi Kan Basıncı Olcumu. http://www.turkhipertansiyon.org/dogruKanBasinci.php (accessed on 08 January, 2022).